- Home
- MRSN vs ACCS Comparison
MRSN vs ACCS Comparison
Compare MRSN & ACCS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MRSN
- ACCS
- Stock Information
- Founded
- MRSN 2001
- ACCS 1988
- Country
- MRSN United States
- ACCS United States
- Employees
- MRSN N/A
- ACCS N/A
- Industry
- MRSN Biotechnology: Pharmaceutical Preparations
- ACCS Publishing
- Sector
- MRSN Health Care
- ACCS Consumer Discretionary
- Exchange
- MRSN Nasdaq
- ACCS Nasdaq
- Market Cap
- MRSN 40.7M
- ACCS 46.0M
- IPO Year
- MRSN 2017
- ACCS N/A
- Fundamental
- Price
- MRSN $0.36
- ACCS $12.05
- Analyst Decision
- MRSN Strong Buy
- ACCS Strong Buy
- Analyst Count
- MRSN 5
- ACCS 1
- Target Price
- MRSN $5.75
- ACCS $15.00
- AVG Volume (30 Days)
- MRSN 2.3M
- ACCS 9.1K
- Earning Date
- MRSN 08-12-2025
- ACCS 08-07-2025
- Dividend Yield
- MRSN N/A
- ACCS N/A
- EPS Growth
- MRSN N/A
- ACCS N/A
- EPS
- MRSN N/A
- ACCS N/A
- Revenue
- MRSN $34,006,000.00
- ACCS $22,961,000.00
- Revenue This Year
- MRSN N/A
- ACCS $7.67
- Revenue Next Year
- MRSN $1.30
- ACCS N/A
- P/E Ratio
- MRSN N/A
- ACCS N/A
- Revenue Growth
- MRSN N/A
- ACCS 6.92
- 52 Week Low
- MRSN $0.26
- ACCS $7.61
- 52 Week High
- MRSN $2.83
- ACCS $13.35
- Technical
- Relative Strength Index (RSI)
- MRSN 46.82
- ACCS N/A
- Support Level
- MRSN $0.35
- ACCS N/A
- Resistance Level
- MRSN $0.39
- ACCS N/A
- Average True Range (ATR)
- MRSN 0.03
- ACCS 0.00
- MACD
- MRSN -0.00
- ACCS 0.00
- Stochastic Oscillator
- MRSN 12.30
- ACCS 0.00
About MRSN Mersana Therapeutics Inc.
Mersana Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing antibody-drug conjugates (ADCs) that offer a clinically meaningful benefit for cancer patients with unmet needs. The Company's next-generation ADC platforms include Dolasynthen, which delivers a proprietary auristatin payload, and Immunosynthen, which delivers a proprietary stimulator of interferon genes (STING) agonist payload. Its pipeline includes Emi-Le (XMT-1660), XMT-2056, XMT-2068, and XMT-2175.
About ACCS ACCESS Newswire Inc. Common Stock
ACCESS Newswire Inc is a Public Relations (PR) and Investor Relations (IR) solutions provider. The group focuses on innovation, customer service, and value-driven offerings, ACCESS Newswire empowers brands.